Ian Miscampbell
drug development
Macrophage Pharma
Denmark
Biography
IAN MISCAMPBELL an has served as Chief Finance Officer and as Chief Operating Officer in a number of publicly quoted and privately owned healthcare and drug development companies, including Reneuron, KS Biomedix, Microscience, Oxford Immunotec, William Ransom and York Pharma. He was responsible for numerous M&A and licensing transactions and has completed multiple financing and re-financing transactions, successfully raising in excess of £100m in equity, debt and grant finance. Having worked as Finance Director in a healthcare fund management business, Ian left in 2010 to establish Sixth Element Capital, where he is Managing Partner. Ian was appointed a Fellow of the Institute of Chartered Accountants in England and Wales in 2011.
Research Interest
He was responsible for numerous M&A and licensing transactions and has completed multiple financing and re-financing transactions, successfully raising in excess of £100m in equity, debt and grant finance.
